<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:5pt Arial, sans-serif; }
 .font1 { font:6pt Arial, sans-serif; }
 .font2 { font:7pt Arial, sans-serif; }
 .font3 { font:10pt Arial, sans-serif; }
 .font4 { font:11pt Arial, sans-serif; }
 .font5 { font:17pt Arial, sans-serif; }
 .font6 { font:11pt Segoe UI, sans-serif; }
 .font7 { font:22pt Segoe UI, sans-serif; }

</style>
</head>
<body><a name="caption1"></a>
<h6><a name="bookmark0"></a><span class="font5"><a name="bookmark1"></a>Morgan Stanley | </span><span class="font2" style="font-weight:bold;">RESEARCH</span></h6>
<p><span class="font2" style="font-style:italic;">December 4, 2023 10:06 AM GMT</span></p>
<p><span class="font4">Medical Technology I North America</span></p>
<p><span class="font7">2024 Outlook: Moving Past GLP-1s</span></p>
<p><span class="font6">Given the material de-rating, we're upgrading our Industry View on MedTech to Attractive given limited expected impact from GLP-1s in our eyes. Volumes remain in strong shape, and capital equipment is looking healthy.</span></p>
<p><span class="font3">Key Takeaways</span></p>
<ul style="list-style:none;"><li>
<p><span class="font2">■ &nbsp;&nbsp;&nbsp;Moving US MedTech industry view to Attractive from In-Line following strong relative de-rating.</span></p></li>
<li>
<p><span class="font2">■ &nbsp;&nbsp;&nbsp;GLP-1 work suggests Limited impact in the next 10 years across the vast majority of our names.</span></p></li>
<li>
<p><span class="font2">■ &nbsp;&nbsp;&nbsp;Coverage expanded to include RXST, GKOS, STAA, and RBOT.</span></p></li>
<li>
<p><span class="font2">■ &nbsp;&nbsp;&nbsp;Key OW's include MDT, RXST, BSX, PODD, TFX, SWAV, ATEC and SIBN.</span></p></li>
<li>
<p><span class="font2">■ &nbsp;&nbsp;&nbsp;More cautious on ALC, and still cautious on AGTI, EMBC, and IART.</span></p></li></ul>
<p><span class="font2">Getting more positive on the industry: Back in May we were somewhat more cautious on US MedTech with valuation sitting 10-15% above the 10 year S&amp;P relative range. But, a combination of rising 10 year rates and GLP-1 pressures have pushed valuation down to a relative c. 1% discount. Frankly, we think the pressure from GLP-1s is overdone, with limited impact to most of our sub-industries over the next decade (e.g. see our diabetes work here). Indeed, smoking offers a natural parallel, where rates of connected surgeries and healthcare consumption increased materially over the period of a precipitous decline in smoking. Given the industry derating (c. 15%) vs strong fundamentals, we're getting more positive on the industry overall.</span></p>
<p><span class="font2">Ophthalmology in focus: Today we have expanded our coverage of ophthalmology substantially, picking up RXST (here), GKOS (here), and STAA (here). Our new work suggests a wave of c. 25mn post-refractive (laser eye surgery) patients are set to enter the cataract market, pressuring rates of premium IOL implantation (-ve for ALC which we downgrade to UW) and beneficial to RXST (initiate OW) who's platform has disproportionate success in post-refractive patients (c. 3-4x higher win rate). We initiate on STAA at EW as while we see the EVO ICL platform as highly differentiated, limited visibility on China (c. 55% of sales) and street numbers for the US being a touch high limit upside. Finally for GKOS, we see strong growth in 2024 from early pipeline launches and competitive share capture, but at c. 8x sales, we feel this is already well captured in expectations.</span></p>
<p><span class="font2">More positive on TFX and PODD, still bullish MDT and SIBN: As part of the more positive view on US MedTech overall, we’re upgradingTFX and PODD to OW. Trading at c. 15x for &gt;6% organic growth, we see TFX as too cheap vs the quality of</span></p>
<div>
<p><span class="font4">FOUNDATION</span></p>
</div><br clear="all">
<div>
<p><span class="font0">MORGAN STANLEY &amp;C0 LLC</span></p>
<p><span class="font2">Patrick A. Wood, CFA</span></p>
<p><span class="font0">Equity Analyst</span></p>
<p><span class="font0">PamdtWooligmaganstanley con &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+1 212 351 -1300</span></p>
<p><span class="font2">Drew Ranieri</span></p>
<p><span class="font0">Equity Malyst</span></p>
<p><span class="font0">Drew Raraen@magaistanley can &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1212 351- 5545</span></p>
<p><span class="font0">MORGAN STANLEY SCO INTERNATIONAL PLC*</span></p>
<p><span class="font2">Kalium L Titchmarsh</span></p>
<p><span class="font0">Equity Malyst</span></p>
<p><span class="font0">Kalium Ttdimarshgmcrganstæley con &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;»44 20 7677-9587</span></p>
<p><span class="font0">MORGAN STANLEY SCO LLC</span></p>
<p><span class="font2">Jakob Dodd</span></p>
<p><span class="font0">Research Associate</span></p>
<p><span class="font0">Jd&lt;ohDodd@maganstarieycan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1212 351 0797</span></p>
<p><span class="font2">Anna Ractliffe</span></p>
<p><span class="font0">Research Associate</span></p>
<p><span class="font0">MnaRactliffegrno-ganstaileycan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1212 3514342</span></p>
<p><span class="font2">Roberto Valdes Sanchez Navarro</span></p>
<p><span class="font0">Research Associate</span></p>
<p><span class="font0">RcbertoVddes Sanchez NavarrognKfganstarley con *1 212 351-1853</span></p>
</div><br clear="all">
<div>
<p><span class="font2" style="font-weight:bold;">MEDICAL TECHNOLOGY</span></p>
<p><span class="font2" style="font-weight:bold;">North America</span></p>
<table border="1">
<tr><td colspan="2" style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Industry View</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Attractive</span></p></td></tr>
<tr><td colspan="3" style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">WHAT'S CHANGED</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">Medical Technology</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">From</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">To</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Industry View</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">In-Line</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Attractive</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">Alcon Inc (ALC.N)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">From</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">To</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Rating</span></p></td><td colspan="2" style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Equal-weight Underweight</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Price Target</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">$85.00</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">$65.00</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">Teleflex Inc. (TFX.N)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">From</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">To</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Rating</span></p></td><td colspan="2" style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Equal-weight Overweight</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">Insulet Corp. (PODD.O)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">From</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">To</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Rating</span></p></td><td colspan="2" style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Equal-weight Overweight</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Price Target</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">$185.00</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">$234.00</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">Staar Surgical Co (STAA.O)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">From</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">To</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Rating</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">NA</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Equal-weight</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Price Target</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">$0.00</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">$35.00</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">Glaukos (GKOS.N)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">From</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">To</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Rating</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">NA</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Equal-weight</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Price Target</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">$0.00</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">$65.00</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">RxSight Inc (RXST.O)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">From</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">To</span></p></td></tr>
</table>
</div><br clear="all">
<div>
<p><span class="font1">Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.</span></p>
<p><span class="font1">For analyst certification and other important disclosures, referto the Disclosure Section, located at the end of this report.</span></p>
</div><br clear="all">
<div>
</div><br clear="all">
<p><span class="font1">+= Analysts employed by non-U.S. affiliates are not registered</span></p>
<p><span class="font1">with FINRA, may not be associated persons of the member</span></p>
<p><span class="font1">and may not be subject to FINRA restrictions on</span></p>
<p><span class="font1">communications with a subject company, public appearances</span></p>
<p><span class="font1">and trading securities held by a research analyst account</span></p>
</body>
</html>